menu
    • menu
    [{"orgOrder":0,"company":"iTolerance","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"iTOL-101","moa":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"iTolerance","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"iTolerance \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"iTolerance \/ Not Applicable"},{"orgOrder":0,"company":"iTolerance","sponsor":"Diabetes Research Institute","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"Allogenic Pancreatic Islets","moa":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"iTolerance","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"iTolerance \/ Diabetes Research Institute","highestDevelopmentStatusID":"4","companyTruncated":"iTolerance \/ Diabetes Research Institute"},{"orgOrder":0,"company":"iTolerance","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Allogeneic Stem Cell-derived Pancreatic Islets","moa":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"iTolerance","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Implant","sponsorNew":"iTolerance \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"iTolerance \/ Not Applicable"},{"orgOrder":0,"company":"iTolerance","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"iTOL-100","moa":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"iTolerance","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"iTolerance \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"iTolerance \/ Not Applicable"},{"orgOrder":0,"company":"iTolerance","sponsor":"Kadimastem","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"Allogenic Pancreatic Islet Cell","moa":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"iTolerance","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"iTolerance \/ Kadimastem","highestDevelopmentStatusID":"4","companyTruncated":"iTolerance \/ Kadimastem"},{"orgOrder":0,"company":"iTolerance","sponsor":"BIRD Foundation","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Funding","leadProduct":"Allogenic Pancreatic Islet Cell","moa":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"iTolerance","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"iTolerance \/ BIRD Foundation","highestDevelopmentStatusID":"4","companyTruncated":"iTolerance \/ BIRD Foundation"},{"orgOrder":0,"company":"iTolerance","sponsor":"Northway Biotechpharma","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Partnership","leadProduct":"iTOL-102","moa":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"iTolerance","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"iTolerance \/ iTolerance","highestDevelopmentStatusID":"4","companyTruncated":"iTolerance \/ iTolerance"},{"orgOrder":0,"company":"iTolerance","sponsor":"Kadimastem","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Allogeneic Stem Cell-derived Pancreatic Islets","moa":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"iTolerance","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Implant","sponsorNew":"iTolerance \/ Kadimastem","highestDevelopmentStatusID":"4","companyTruncated":"iTolerance \/ Kadimastem"}]

    Find Clinical Drug Pipeline Developments & Deals by iTolerance

    Menu

    iTolerance

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            iTolerance

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            iTolerance

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Allogeneic Stem Cell-derived Pancreatic Islets

                            Therapeutic Area : Endocrinology

                            Study Phase : Preclinical

                            Sponsor : Kadimastem

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            iTolerance, Inc. and Kadimastem Ltd. Submit Initial Targeted Engagement for Regulatory Advice on CBER Products...

                            Details : iTOL-102 is our lead program that is developed Using our proprietary SA-FasL biotin-PEG microgel platform, which being developed as a potential cure for Type 1 Diabetes without the need for chronic immunosuppression.

                            Brand Name : iTOL-102

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            November 07, 2023

                            Lead Product(s) : Allogeneic Stem Cell-derived Pancreatic Islets

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Preclinical

                            Sponsor : Kadimastem

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            iTolerance

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            iTolerance

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : iTOL-102

                            Therapeutic Area : Endocrinology

                            Study Phase : Preclinical

                            Recipient : Northway Biotechpharma

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            iTolerance, Inc. and Northway Biotech Announce Partnership Agreement for the Manufacturing of Streptavidin-Fas...

                            Details : The agreement aims for the commercialising of Folotyn (Pralatrexate), a dihydrofolate reductase inhibitor indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma, in the People's Republic of China.

                            Brand Name : iTOL-102

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            August 01, 2023

                            Lead Product(s) : iTOL-102

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Preclinical

                            Recipient : Northway Biotechpharma

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            iTolerance

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            iTolerance

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Allogenic Pancreatic Islet Cell

                            Therapeutic Area : Endocrinology

                            Study Phase : Preclinical

                            Sponsor : Kadimastem

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            iTolerance, Inc. and Kadimastem Enter into Collaboration Agreement for Development of a Potential Cure for Typ...

                            Details : Under the agreement, Kadimastem will supply its advanced cell product, IsletRx and iTolerance will provide its iTOL-100 immunomodulatory technology for the development of iTOL-102 (allogenic pancreatic islet cell) for the treatment of Type 1 Diabetes.

                            Brand Name : iTOL-102

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            May 18, 2023

                            Lead Product(s) : Allogenic Pancreatic Islet Cell

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Preclinical

                            Sponsor : Kadimastem

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            iTolerance

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            iTolerance

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Allogenic Pancreatic Islet Cell

                            Therapeutic Area : Endocrinology

                            Study Phase : Preclinical

                            Sponsor : BIRD Foundation

                            Deal Size : $1.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            iTolerance, Inc. Receive US $1.0 Million Grant from the BIRD Foundation

                            Details : The funding will support the aforementioned technologies towards clinical application of iTOL-102, an allogeneic cell product intended to utilize stem cells to derive pancreatic islets which allows an inexhaustible supply of insulin-producing cells.

                            Brand Name : iTOL-102

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            May 18, 2023

                            Lead Product(s) : Allogenic Pancreatic Islet Cell

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Preclinical

                            Sponsor : BIRD Foundation

                            Deal Size : $1.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            iTolerance

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            iTolerance

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : iTOL-100

                            Therapeutic Area : Endocrinology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            iTolerance, Inc. Announces Issuance of U.S. Patent Covering Proprietary Regenerative SA-FasL Microgel Technolo...

                            Details : iTOL-100 acts to generate localized immune tolerance, allogeneic stem cell-derived pancreatic islets will be implanted in the body, which are capable of secreting insulin in response to sugar intake. It provides a potentially inexhaustible supply of insu...

                            Brand Name : iTOL-100

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            April 20, 2023

                            Lead Product(s) : iTOL-100

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            iTolerance

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            iTolerance

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Allogeneic Stem Cell-derived Pancreatic Islets

                            Therapeutic Area : Endocrinology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            iTolerance, Inc. Completes Pre-IND Meeting with U.S. FDA for Development Program as a Potential Cure for Type ...

                            Details : iTOL-100, generates localized immune tolerance, allogeneic stem cell-derived pancreatic islets will be implanted in the body. These stem cells are potentially capable of secreting insulin in response to sugar intake, similar to how native pancreatic isle...

                            Brand Name : iTOL-102

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            March 01, 2023

                            Lead Product(s) : Allogeneic Stem Cell-derived Pancreatic Islets

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            iTolerance

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            iTolerance

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Allogenic Pancreatic Islets

                            Therapeutic Area : Endocrinology

                            Study Phase : Preclinical

                            Sponsor : Diabetes Research Institute

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            iTolerance, Inc. Enters into Master Services Agreement with the Diabetes Research Institute (DRI) at the Unive...

                            Details : DRI will assist in advancing potential of iTOL-100 platform technology is a biotechnology-derived Strepavidin-FasL fusion protein, mixed with a biotin-PEG microgel (SA-FasL microgel) to enable engraftment and long-term survival of transplanted insulin pr...

                            Brand Name : iTOL-102

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            January 30, 2023

                            Lead Product(s) : Allogenic Pancreatic Islets

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Preclinical

                            Sponsor : Diabetes Research Institute

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            iTolerance

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            iTolerance

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : iTOL-101

                            Therapeutic Area : Endocrinology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            iTolerance, Inc. to Present at the Virtual Investor Pioneering Regenerative Medicine Without Immunosuppression...

                            Details : iTOL-101 developed for Type 1 Diabetes and in pre-clinical non-human primate study, pancreatic islet cells co-implanted with iTOL-101 exhibited long-term function with control blood glucose levels and restoration of insulin secretion without use of chron...

                            Brand Name : iTOL-101

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            October 24, 2022

                            Lead Product(s) : iTOL-101

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth